# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to...
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a ...
On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeove...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attracti...
Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis Bid...
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrus...
Wells Fargo analyst Derek Archila downgrades MorphoSys (NASDAQ:MOR) from Overweight to Equal-Weight and raises the price tar...